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Stroke Prediction in Atrial Fibrillation*William Whang, MD, MS, David J. Shim, MD, PHDSEE PAGE 1658W illiam Osler characterized medicine as ascience of uncertainty and an art of prob-ability (1), and this is especially true in
making treatment decisions to prevent stroke in pa-
tients with atrial ﬁbrillation (AF), the most common
cardiac arrhythmia. For most cardiologists, the deci-
sion to initiate anticoagulation in patients with AF
starts with an attempt to quantify the patient’s stroke
risk. It has been recognized for some time that throm-
boembolic risk in patients with AF depends less on
the “quantity” or “severity” of their AF and more on
other clinical characteristics. Epidemiological and
observational research into these characteristics has
yielded a number of risk stratiﬁcation schemes to
help guide anticoagulation decisions.
The ﬁrst risk stratiﬁcation scheme to gain wide-
spread acceptance was the CHADS2 score (2), which
was particularly advantageous due to its relative ease
of use. The CHADS2 system stratiﬁed patients into
low-, moderate-, and high-risk categories and became
widely used for estimates of stroke risk in the clinical
setting. Additional thromboembolic risk factors were
recognized and incorporated into the subsequent
CHA2DS2-VASc score (congestive heart failure, hy-
pertension, age $75, diabetes mellitus, prior stroke or
transient ischemic attack, vascular disease, age 65 to
74, female score) (3), with modiﬁcation of the age
component and inclusion of vascular disease
(myocardial infarction, peripheral vascular disease, or
aortic plaque) and sex. More recently, the anti-
coagulation and risk factors in atrial ﬁbrillation
(ATRIA) score was developed and validated on the*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Department of Medicine, Columbia University College of Phy-
sicians and Surgeons, New York, New York. Both authors have reported
that they have no relationships relevant to the contents of this paper to
disclose.basis of a sample of patients from Kaiser Permanente
Northern California (4). The ATRIA score was re-
ported to have better performance characteristics on
the basis of the c-index and net reclassiﬁcation index
than prior scoring systems, according to analyses of
the ATRIA-Cardiovascular Research Network cohort.
Compared with CHA2DS2-VASc, the main differences
in the ATRIA score were inclusion of renal dysfunc-
tion and proteinuria, rather than vascular disease,
and a revamped, albeit more complicated, scoring
algorithm for age that incorporated an interaction
with history of ischemic stroke. ATRIA scores ranged
from 0 to 15, and were collapsed into a relatively
expansive low-risk category (0 to 5), as well as
moderate-risk (score of 6) and high-risk (scores of 7 to
15) categories in order to correspond to annualized
stroke rates of <1%, 1 to <2%, and $2% per year.In this issue of the Journal, Chao et al. (5) compare
the performance of ATRIA and CHA2DS2-VASc risk
stratiﬁcation schemes in a large independent cohort
from the Taiwanese National Health insurance
research database, representing over 23 million
enrollees (5). The authors sampled more than 186,000
patients with AF, who were not taking anticoagulant
or antiplatelet medications. Risk scores were esti-
mated on the basis of the ATRIA and CHA2DS2-VASc
models and were related to ischemic stroke frequency
during a mean follow-up of 3.4 years. Their ﬁndings
demonstrate better discriminatory performance with
CHA2DS2-VASc scores than with the ATRIA score,
again according to c-index and net reclassiﬁcation
index (5).
One of the study’s major strengths is its impres-
sively large sample size, allowing for further analyses
that help illustrate the relative merits of the 2 risk
stratiﬁcation schemes speciﬁcally for identiﬁcation of
low-risk patients. Within the substantial group of
patients considered low-risk on the basis of their
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1667ATRIA scores (39.3% of the sample), a higher
CHA2DS2-VASc score was still associated with greater
stroke risk (5). It is noteworthy that within this same
subgroup, higher ATRIA scores were also associated
with risk of stroke (5).
Like many interesting studies, this one leads to a
number of questions and potential avenues for
further research. Why exactly did one scoring system
perform better than the other? Among the more
obvious differences between the two schemes is the
possibility that perhaps vascular disease was more
predictive of stroke in this sample or perhaps renal
disease was less predictive. The type of population
studied is likely to have signiﬁcant impact on the
utility of either factor in stroke prediction. For
instance, in ROCKET AF (Rivaroxaban Once-daily,
oral, direct factor Xa inhibition Compared with
vitamin K antagonism for prevention of stroke and
Embolism Trial in Atrial Fibrillation), reduced creati-
nine clearance was independently predictive of
stroke and thromboembolic risk after adjusting for
standard risk factors (6). However, patients in
ROCKET AF had at least two risk factors for stroke,
and severe renal failure was an exclusion criterion. In
the Loire Valley Atrial Fibrillation Project of patients
with AF identiﬁed from discharge records, although
renal impairment was associated with stroke and
thromboembolism, it did not signiﬁcantly improve
risk prediction when added to CHA2DS2-VASc (7).
Similar examples on both sides can be identiﬁed for
vascular disease, although there is greater support for
its inclusion in risk stratiﬁcation schemes (8). In the
current study from Chao et al. (5), the study sample
excluded patients treated not only with anti-
coagulation with warfarin but also with any anti-
platelet agents such as aspirin. One could postulate
that this might have ampliﬁed the relationship
between vascular disease and stroke risk in this
analysis.
Can the results from the relatively homogeneous
ethnic group in this analysis be extrapolated to other
populations? The cohort in the present study was at
relatively high risk for ischemic stroke, 12.7% during
a mean follow-up of 3.4 years. This incidence rate is
consistent with another recent study that reported
even higher annual risk of stroke, approximately 9%,in a hospital-based cohort from Hong Kong (9). It
is also substantially higher than the 2.0% annu-
alized rate of ischemic stroke in the ATRIA deriva-
tion cohort (4). Perhaps the ATRIA score could be
improved for populations with higher baseline risk
of stroke by recalibrating the designation of low-
risk and intermediate-risk categories. In the present
study, an ATRIA score of 0 or 1 was still associated
with a low stroke rate at 5-year follow-up (1.36
to 1.60 per 100 person-years), comparable to a
CHA2DS2-VASc score of 0 or 1 (1.00 to 1.89 per
100 person-years).
It is also worth mentioning that patients’ perspec-
tives on what constitutes “low-risk” may differ. One
person may accept a stroke risk of 1% per year,
whereas another may accept a higher risk depending
on his or her preferences to avoid bleeding. For some
patients, it may be more useful to provide quantita-
tive risks with ranges to incorporate uncertainty, as
opposed to categories of risk that may give a false
sense of precision. Risk stratiﬁcation schemes can aid
in our clinical decision making only if we use them,
and even with the beneﬁt of validated risk scores,
evidence suggests a tendency to withhold anti-
coagulation in multiple clinical arenas (10,11). Further
research is needed to help deﬁne optimal ways to
convey information to patients with AF and help
improve clinical decision-making (12).
Although prescribing anticoagulant agents for pa-
tients with AF is ultimately a clinical decision to be
made between physician and patient, there is a need
to continue development of more accurate stroke risk
estimators. The study from Chao et al. (5) provides
insight into the relative performance of the ATRIA
and CHA2DS2-VASc scoring systems in a higher risk
cohort. Further research in a variety of populations
will hopefully help us understand the reasons for
differential performance of particular risk stratiﬁca-
tion schemes and allow for more targeted recom-
mendations for individual patients.
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